Clinical trials: Pigmentation Disorder
- Condition Pigmentation Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Acute Kidney Injury
Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different…
- Trial name
- NCT02772276
- Testing
- MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
- Where
- 3 sites in United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Vitiligo
Photocil (Topical) for the Treatment of Vitiligo
Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight.
- Trial name
- NCT01992185
- Testing
- Photocil for Vitiligo
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Applied Biology, Inc.
Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
The purpose of this study was to evaluate the efficacy and safety of afamelanotide, when combined with narrowband ultraviolet B (NB-UVB) phototherapy, in patients with nonsegmental vitiligo.
- Trial name
- NCT04525157
- Testing
- Afamelanotide
- Volunteers
- 21 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Vitiligo
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
- Trial name
- NCT03099304
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 26 sites in United States
- Volunteers
- 157 people
- Sponsor
- Incyte Corporation
Onychomycosis of Toenails
Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
- Trial name
- NCT01302119
- Testing
- AN2690 Topical Solution, 5%, Solution Vehicle
- Where
- 32 sites in United States, Canada
- Volunteers
- 604 people
- Sponsor
- Pfizer
Glaucoma
AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure
The purpose of this study was to assess the safety and efficacy of switching to Azarga from prior pharmacotherapy in patients with open-angle glaucoma.
- Trial name
- NCT01484951
- Testing
- Brinzolamide 1% and timolol 0.5% fixed combination eye drops
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Alcon Research
Lentigines
A Single-Center 2-Arm Study for Lentigines on the Hands
The purpose of this study is to evaluate the effectiveness and safety of two laser systems for improvement of lentigines on the hands.
- Trial name
- NCT02763072
- Testing
- Enlighten Laser, Excel V Laser
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Vitiligo, Melanoma (Skin)
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.
- Conditions
- Vitiligo, Melanoma (Skin), Nonmelanoma Skin Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04969419
- Testing
- Exposure of skin cancer of interest
- Where
- United Kingdom
- Volunteers
- 75,771 people
- Sponsor
- Momentum Data
Onychomycosis of Toenails
Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
- Trial name
- NCT01270971
- Testing
- AN2690 Topical Solution, 5%, Solution Vehicle
- Where
- 27 sites in United States
- Volunteers
- 594 people
- Sponsor
- Pfizer
Glaucoma
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01336569
- Testing
- Travoprost 0.004%/timolol maleate 0.5% fixed combination
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Vitiligo
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
- Trial name
- NCT03468855
- Testing
- ATI-50002 topical solution
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aclaris Therapeutics, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Efficacy of Changing to DUOTRAV® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of changing to DUOTRAV® from prior bimatoprost 0.03%/timolol 0.5% pharmacotherapy in subjects with open-angle glaucoma or ocular hypertension having…
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT01327599
- Testing
- Travoprost 0.004%+Timolol 0.5% ophthalmic solution
- Volunteers
- 60 people
- Sponsor
- Alcon Research
Melasma
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects…
- Trial name
- NCT00669071
- Testing
- Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Galderma R&D
Non-Segmental Vitiligo
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- NCT04927975
- Testing
- Upadacitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04057573
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 76 sites in United States, Bulgaria and 7 more
- Volunteers
- 344 people
- Sponsor
- Incyte Corporation
Poikiloderma of Civatte, Dyschromia
Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
This study will evaluate the safety and efficacy of the Excel V 532 nm KTP laser for the treatment of dyschromia of the neck and/or chest (poikiloderma of Civatte).
- Conditions
- Poikiloderma of Civatte, Dyschromia, Pigmentation Disorders, Telangiectasia
- Trial name
- NCT01491620
- Testing
- 532 nm KTP laser
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Cutera Inc.
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Basal Cell Carcinoma
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
This is a multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with non-Gorlin HF-BCC…
- Trial name
- NCT04155190
- Testing
- Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Nonsegmental Vitiligo With Genital Involvement
A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks.
- Trial name
- NCT05750823
- Testing
- Ruxolitinib Cream
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 49 people
- Sponsor
- Incyte Corporation
Vitiligo
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
- Trial name
- NCT04547998
- Testing
- Control Intervention (UVB), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Avita Medical